24Feb 2019

SERUM IGF-1& URIC ACID IN PATIENTS WITH PARKINSONS DISEASE AND PARKINSON PLUS SYNDROME.

  • MD, Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
  • DM, Department of Neurology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
  • M Phil, Department of Medical Parasitology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
  • MD, DNB, Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background:Development of biomarkers in Parkinson?s disease (PD) and Parkinson Plus Syndrome (PPS) is still at an elementary stage. Recent studies have yielded conflicting results on the role of insulin like growth factor (IGF-1) & uric acid as biomarkers in PD. We evaluated the role of serum IGF-1 and uric acid as diagnostic and prognostic markers in PD. Objectives: 1. To evaluate the role of serum IGF-1 & uric acid as biomarkers for differentiating PD from Parkinson plus syndrome and healthy controls. 2. To study the correlation of levels of serum IGF-1& uric acid with duration and severity of illness in PD. Methods:Current study included 99 patients with Parkinsonism and 68 healthy volunteers. Patients were diagnosed as PD, multisystem atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal ganglionic degeneration (CBGD) as per standard criteria. Written informed consent was obtained from all patients included in the study. All patients underwent complete neurological examination, MMSE (Mini Mental State Examination), UPDRS (Unified Parkinson Disease Rating Scale) and MRI brain. Serum IGF-1 was measured by DRG IGF-1 600 ELISA kit (Catalogue No: 18K116: DRG Instruments Gm BH, Germany). Serum uric acid was measured by INFINITE Uric acid assay kit (Accurex Biomedical PVT.LTD., Mumbai, INDIA). Results:Serum IGF-1 levels were significantly elevated (p<0.01) & uric acid levels were significantly decreased (p<0.01) in PD patients compared to controls, but the difference in serum IGF-1 & uric acid levels in various Parkinsonism groups (PD, YOPD, PSP, MSA, CBGD) were not significant. Conclusion:Serum IGF-1 levels were increased & uric acid decreased in PD. Further studies employing higher sample size and longitudinal measurement of serum IGF-1 and uric acid will help in delineating their role as biomarkers in PD.

  1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol.2006; 5(6):525-35.
  2. Nussbaum RL, Ellis CE. Alzheimer?s disease and Parkinson?s disease. N Engl J Med. 2003; 348(14):1356?64.
  3. Tanner CM, Goldman SM. Epidemiology of Parkinson?s disease. Neurol Clin.1996; 14(2):317?35.
  4. Offen D, Shtaif B, Hadad D, Weizman A, Melamed E, Gil-Ad I. Protective effect of insulin-like-growth factor- 1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease. Neurosci Lett. 2001; 316(3):129?32.
  5. Godau J, Herfurth M, Kattner B, Gasser T, Berg D. Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease. J Neurol Neurosurg Psych. 2010; 81(5):536?8.
  6. Pellecchia MT, Santangelo G, Picillo M, Pivonello R, Longo K, Pivonello C, Vitale C, Amboni M, De Rosa A, Moccia M, Erro R, De Michele G, Santoro L, Colao A, Barone P. Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug na?ve Parkinson's disease. Eur J Neurol. 2014;21(5):802-7.
  7. Godau J, Knauel K, Weber K, Brockmann K, Maetzler W, Binder G, Berg D. Serum insulin like growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease. Arch Neurol. 2011;68(7):925-31.
  8. Picillo M, Erro R, Santangelo G, Pivonello R, Longo K, Pivonello C, Vitale C, Amboni M, Moccia M, Colao A, Barone P, Pellecchia MT. Insulin-like growth factor-1 and progression of motor symptoms in early, drug-na?ve Parkinson's disease. J Neurol. 2013; 260(7):1724-30.
  9. Numao A, Suzuki K, Miyamoto M, Miyamoto T, Hirata K. Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Park Relat Disord. 2014; 20(2):212?6.
  10. Mielke MM,? Maetzler W. A ?bird?s eye? view on the current status and potential? benefits of blood biomarkers for Parkinson's disease. Biomark Med. 2014; 8(2): 225?7.
  11. Golbe LI.? Progressive supranuclear palsy. Semin Neurol. 2014; 34(2):151-9.
  12. Bernhard FP, Heinzel S, Binder G, Weber K, Apel A, Roeben B, Deuschle C, Maechtel M, Heger T, Nussbaum S, Gasser T, Maetzler W, Berg D. Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors. PLoS One. 2016;11(3):e0150552.
  13. Schaefer S, Vogt T, Nowak T, Kann PH. Pituitary function and the somatotrophic system in patients with idiopathic Parkinson?s disease under chronic dopaminergic therapy. J Neuroendocrinol. 2008; 20(1):104-9.
  14. Tuncel D, Inanc Tolun F, Toru I. Serum insulin-like growth factor-1 and nitric oxide levels in parkinson?s disease. Mediators Inflamm. 2009; 2009:132464.
  15. Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM. Observations on serum uric acid levels and the risk of idiopathic Parkinson?s disease. Am J Epidemiol. 1996; 144:480?4.
  16. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum uric acid levels and the risk of Parkinson?s disease. Ann Neurol. 2005; 58:797?800.
  17. Brody DM, Litvan I, Warner S, Riley DE, Hall DA, Kluger BM,et al. Relationship between uric acid levels and progressive supranuclear palsy. Mov Disord. 2016
  18. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson?s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatr. 1992; 55(3):181-4.
  19. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996; 47(1):1-9.
  20. Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., ? Vidailhet, M. (2008). Second consensus statement on the diagnosis of multiple system atrophy. Neurology, 71(9), 670?6.
  21. Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, Boxer AL, Dickson DW, Grossman M, Hallett M, Josephs KA, Kertesz A, Lee SE, Miller BL, Reich SG, Riley DE, Tolosa E, Tr?ster AI, Vidailhet M, Weiner WJ. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013; 80(5):496-503.
  22. Fahn S, Elton R, Members of the UPDRS Development Committee. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson?s Disease, Vol 2. Florham Park, NJ. Macmillan Health Care Information 1987, 153-163, 293-304.
  23. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17(5):427-42.
  24. Li DH, He YC, Quinn TJ, Liu J. Serum Insulin-Like Growth Factor-1 in Patients with De Novo, Drug Na?ve Parkinson's Disease: A Meta-Analysis. PLoS One. 2015; 10(12):e0144755.

[Missamma Mulagala, Ritu Shree, Gunjan Goyal, Manoj K Goyal, Sahil Mehta, Manish Modi, B R Mittal and Bikash Medhi. (2019); SERUM IGF-1& URIC ACID IN PATIENTS WITH PARKINSONS DISEASE AND PARKINSON PLUS SYNDROME. Int. J. of Adv. Res. 7 (Feb). 934-940] (ISSN 2320-5407). www.journalijar.com

Dr. Bikash Medhi
MD Pharmacology

DOI:

Article DOI: 10.21474/IJAR01/8565      
DOI URL: https://dx.doi.org/10.21474/IJAR01/8565

Download Full Paper

Download PDF No. of Downloads: 34 | No. of Views: 167